AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationStem CellsSalvage TherapyPeripheral Blood Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsTransplantation, HomologousHodgkin DiseaseTransplantation ConditioningMelphalanMultiple MyelomaCombined Modality TherapyTreatment OutcomeHematopoietic Stem CellsRemission InductionAdult Stem CellsEtoposideDisease-Free SurvivalEmbryonic Stem CellsCyclophosphamideRecurrenceBone Marrow TransplantationLymphoma, Non-HodgkinGraft vs Host DiseaseCarmustineCytarabineMyeloablative AgonistsSurvival RateHematopoietic Stem Cell MobilizationHematologic NeoplasmsSurvival AnalysisThiotepaVincristineRetrospective StudiesBone Marrow PurgingCell DifferentiationDoxorubicinWhole-Body IrradiationPrognosisMesenchymal Stem Cell TransplantationBusulfanGraft SurvivalIfosfamideAmyloidosisLymphoma, Mantle-CellLiver TransplantationFollow-Up StudiesDexamethasoneAntigens, CD34Antibodies, Monoclonal, Murine-DerivedBoronic AcidsAntineoplastic AgentsTime FactorsPyrazinesAntineoplastic Agents, AlkylatingLymphoma, FollicularTransplantation ChimeraLymphomaGranulocyte Colony-Stimulating FactorCord Blood Stem Cell TransplantationThalidomideLymphoma, T-Cell, PeripheralTissue DonorsPrednisoneAutograftsLeukapheresisCell TransplantationInduction ChemotherapyLymphoma, Large B-Cell, DiffuseCisplatinPluripotent Stem CellsLeukemia, Myeloid, AcuteKidney TransplantationPodophyllotoxinNeoplasm, ResidualNeoplasm Recurrence, LocalMesenchymal Stromal CellsStem Cell NicheMaintenance ChemotherapyNeural Stem CellsMyelodysplastic SyndromesImmunosuppressive AgentsProspective StudiesChemotherapy, AdjuvantHistocompatibility TestingCarboplatinLymphoma, B-CellDrug Administration ScheduleInduced Pluripotent Stem CellsMitoxantroneNeoplasms, Second PrimaryBleomycinHistocompatibilityIdarubicinBlood Component RemovalLeukemiaHematopoiesisLeukemia, Plasma CellBone Marrow Cells
LymphomasRelapsed or refractoryDiffuse large ceHigh-doseRegimensClassical HodgkinTransplantHodgkin's LymphomaCandidates for autologousClassic Hodgkin lymphomaRegimenTherapy and autologousImmunotherapyNivolumabBoneASCTDiseaseTumorHematopoietic progenitorMantle cell lymMultiple myelomaPatients undergoingRituximab and chemotherapyFollicular lymphomaDLBCLIfosfamideClinicalProgenitor cellsSurvivalPrognosticLiver transplantation2018Combination chemotherapyEtoposideLymphoma patientsFindingsRadiation therapyHSCTTreatmentRelapseAllogeneic stemEfficacyAntigenPositronOncologyAggressiveNodularLarge B-cell lymPTCLConventionalPediatricHaematopoietic
Lymphomas17
  • T-cell immunophenotype constitutes an unfavorable prognostic factor in aggressive non-Hodgkin's lymphomas. (cun.es)
  • High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas. (cun.es)
  • Salvage treatment results with HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell lymphomas. (cun.es)
  • MCL represents 2-10% of all non-Hodgkin lymphomas. (medscape.com)
  • [ 6 ] In the International Lymphoma Classification Project, it accounted for 8% of all non-Hodgkin lymphomas (NHLs). (medscape.com)
  • called lymphocytes and is distinguished from other lymphomas by the presence of a particular kind of cancer cell called a Reed-Sternberg cell. (msdmanuals.com)
  • Lymphomas are cancers of a specific type of white blood cells known as lymphocytes. (msdmanuals.com)
  • Non-Hodgkin Lymphomas Non-Hodgkin lymphomas are a diverse group of cancers of types of white blood cell called lymphocytes. (msdmanuals.com)
  • Zhang QY, Foucar K. Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. (medscape.com)
  • Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. (u-tokyo-hemat.com)
  • The aggressive B-cell lymphomas BL, DHL, and HGBL, NOS are unique diseases with specific pathogenesis and biology. (cancernetwork.com)
  • 1 A significant minority of these cases were the especially aggressive B-cell lymphomas Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL), the latter of which includes the histologic subtypes HGBL with MYC and BCL2 and/or BCL6 translocations (conventionally referred to as double-hit lymphoma [DHL]) and HGBL, not otherwise specified (NOS). (cancernetwork.com)
  • The belief that T-cell lymphomas have a worse prognosis than B-cell lymphomas remains controversial. (oncolink.org)
  • REAL/WHO- [6] - classification includes leukemias and lymphomas, with 3 categories based on lineage and morphology (Hodgkin, B cell, and T/NK cell). (oncolink.org)
  • MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. (pharmateca.ru)
  • The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. (sc-ctsi.org)
  • Relatively low levels of CD20 are expressed on CLL B cells, compared to normal B or neoplastic B cells of other lymphomas. (cancertreatmenttoday.org)
Relapsed or refractory10
  • DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. (wikipedia.org)
  • In a phase II trial reported in JAMA Oncology , Locke J. Bryan, MD , and colleagues found that the combination of pembrolizumab with ICE chemotherapy (a regimen including ifosfamide, carboplatin, and etoposide) produced a high rate of complete response in patients with relapsed or refractory classical Hodgkin lymphoma who were candidates for autologous stem cell transplantation (SCT). (ascopost.com)
  • As stated by the investigators, "To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic[al] Hodgkin lymphoma in patients destined for an autologous SCT. (ascopost.com)
  • In the U.S. investigator-initiated multicenter study, 37 evaluable patients with relapsed or refractory disease after one or two lines of chemotherapy were enrolled between April 2017 and October 2020. (ascopost.com)
  • The investigators concluded, "Results suggest that the addition of pembrolizumab to ICE chemotherapy was well tolerated and highly effective in comparison with prior reports of chemotherapy-only regimens, supporting further investigation in patients with relapsed or refractory classic[al] Hodgkin lymphoma eligible for an autologous SCT. (ascopost.com)
  • Autologous BMT is used as a salvage therapy for patients with relapsed or refractory Hodgkin's lymphoma. (koruhastanesi.com)
  • Scholars@Duke publication: Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. (duke.edu)
  • Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
  • Evaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma. (medivizor.com)
  • In a nutshell This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
Diffuse large ce1
  • The diagnosis of diffuse large cell lymphoma is usually confirmed after positive findings are obtained from a lymph node biopsy specimen. (medscape.com)
High-dose11
  • It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. (wikipedia.org)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. (nih.gov)
  • Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation. (johnshopkins.edu)
  • High-dose CBV (cyclophosphamide, carmustine, and etoposide) in combination with autologous HCT achieves survival rates of approximately 50% at 5 years in recurrent or refractory Hodgkin's disease (HD). (duke.edu)
  • Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. (medscape.com)
  • Radiation Therapy for Young Children Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant for Primary Brain Tumors. (ucdenver.edu)
Regimens8
  • Second-line chemotherapy regimens vary, depending on whether hematopoietic stem cell transplantation (HSCT) is being considered. (medscape.com)
  • In a univariate analysis, factors significantly associated with improved DFS included absence of B symptoms (fever, night sweats and unexplained weight loss) at transplant, response to pre-transplant salvage chemotherapy, less tumor bulk at time of transplant, and fewer prior treatment regimens. (umn.edu)
  • To date, the standard chemotherapy regimen is still uncertain, although two regimens as paclitaxel-platinum (PP) and ifosfamide-platinum (IP) regimens are most commonly used. (bvsalud.org)
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Check specific guidelines for restaging and dosage adjustments for chemotherapy and/or radiation therapy depending on positron-emission tomography (PET) scanning throughout the various regimens. (medscape.com)
  • Regimens that combine chemotherapy and radiation therapy (RT) have replaced RT alone for treatment of early-stage, favorable disease. (medscape.com)
  • Most regimens of induction chemotherapy include drugs that cross the blood-brain barrier (BBB) in conventional doses. (biomedcentral.com)
Classical Hodgkin2
  • Treatment protocols for classical Hodgkin lymphoma (HL) are provided below, including treatment for early-stage, advanced-stage, and relapsed/refractory disease. (medscape.com)
  • Some background Classical Hodgkin lymphoma (cHL) is a cancer of. (medivizor.com)
Transplant13
  • Stepwise multivariate analysis showed that the absence of B symptoms at time of transplant was independently and significantly associated with improved DFS after transplantation. (umn.edu)
  • CBV with autologous stem cell support can produce durable remissions with acceptable toxicity in a substantial proportion of patients who are asymptomatic at time of transplant. (umn.edu)
  • The authors describe a 16-year-old with PTCL, treated with chemotherapy and autologous stem cell transplant. (bvsalud.org)
  • The Koru Hospital Bone Marrow Transplant Center is a state-of-the-art medical facility that offers advanced stem cell therapy for a range of hematological disorders. (koruhastanesi.com)
  • Time trends in risk and risk determinants of non-hodgkin lymphoma in solid organ transplant recipients. (medscape.com)
  • All three of the responders failed multiple lines of prior therapy including chemotherapy, CD19-directed autologous CAR T cell therapy, and allogeneic stem cell transplant. (cellectis.com)
  • These treatment responses in combination with the safety data are very encouraging for patients with r/r B-cell ALL who have limited, if any, treatment options, especially for those who have failed prior CD19 directed CAR T-cell therapy and allogeneic stem cell transplant', said Nitin Jain, M.D., The University of Texas MD Anderson Cancer Center, Department of Leukemia, and coordinating investigator for the BALLI-01 study. (cellectis.com)
  • If they respond, then we take them to an autologous bone marrow transplant. (oncdata.com)
  • Even if they do respond and go through an autologous transplant, among patients who have relapsed within 12 months after receiving chemoimmunotherapy, only a quarter of these patients actually experience durable remission. (oncdata.com)
  • TRANSFORM is a randomized pivotal global multicenter phase 3 trial testing liso-cel against the standard of care, which is salvage chemotherapy followed by an autologous stem cell transplant in patients with primary relapsed/refractory LBCL in the second-line setting. (oncdata.com)
  • On the other hand, patients in the standard-of-care arm received the standard three cycles of salvage chemotherapy followed by autologous transplant if they were to respond. (oncdata.com)
  • On the other hand, in the standard-of-care arm, only about 46% of patients responded to salvage and went on to get an autologous transplant. (oncdata.com)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
Hodgkin's Lymphoma10
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Autologous BMT is used as a consolidation therapy for patients with high-risk non-Hodgkin's lymphoma. (koruhastanesi.com)
  • Allogeneic BMT is used as a salvage therapy for certain types of lymphoma, such as Hodgkin's lymphoma and non-Hodgkin's lymphoma. (koruhastanesi.com)
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. (medscape.com)
Candidates for autologous1
  • 12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. (nih.gov)
Classic Hodgkin lymphoma1
  • Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma. (medivizor.com)
Regimen2
  • Seven received radiation as part of the conditioning regimen, and four received radiation after transplantation. (ascopost.com)
  • Alemtuzumab was added to the LD regimen to sustain host T-cell and Natural Killer (NK) cell depletion and to promote UCART22 cell expansion and persistence. (cellectis.com)
Therapy and autologous1
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
Immunotherapy6
  • Chemotherapy, combinations of chemotherapy and immunotherapy, and radiation therapy are used for treatment. (msdmanuals.com)
  • Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
  • Most important aspect of therapy is anti CD20 antibody, the Rituximab, which is a kind of immunotherapy or targeted therapy and attacks the CD20 antigen on the cancer cells. (lymphomaindia.com)
  • Multiagent chemotherapy + immunotherapy should be reserved for patients who are having advanced stages of disease and having symptoms/ difficulties related to it. (lymphomaindia.com)
  • Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. (wustl.edu)
  • Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non-small cell lung cancer (NSCLC), according to data presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. (ascopost.com)
Nivolumab1
  • Nivolumab + BV showed durable safety and efficacy as salvage in patients with R/R PMBL after 3-year follow-up, with no new safety signals. (ashpublications.org)
Bone9
ASCT1
Disease24
  • Earlier application of transplantation or development of additional effective antineoplastic modalities will be required to improve the results of transplantation for patients with advanced Hodgkin's disease. (umn.edu)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. (nih.gov)
  • Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. (nih.gov)
  • Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge. (nih.gov)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment. (johnshopkins.edu)
  • While effective, broad use of CAR T-cell therapies is limited by potential for life-threatening toxicities, challenges related to manufacturing a patient-specific product, high costs and inadequate reimbursement, and incomplete or unsustained disease response. (ajmc.com)
  • Research in CAR T-cell therapy is expected to improve tolerability and expand indications to more types of malignancies and earlier phases of disease. (ajmc.com)
  • Allogeneic stem cell transplantation should be considered for refractory disease or for very early relapsing disease. (lymphomaindia.com)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • The nature of disease (indolent vs. aggressive) is correlated to the stage of lymphocytic differentiation of the malignant cells. (oncolink.org)
  • Malignant blast cells (i.e. diffuse large B-cell lymphoma) are fast-growing and result in aggressive disease, whereas malignant mature lymphocytes (i.e. follicular lymphoma) behave indolently. (oncolink.org)
  • Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. (medscape.com)
  • HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. (medscape.com)
  • Two cases entered CR and one case required further chemotherapy for relapsed disease. (hku.hk)
  • Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE. (lookformedical.com)
  • The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. (lookformedical.com)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
  • Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. (apbmt.org)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
  • Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. (uchicago.edu)
  • Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. (uchicago.edu)
Tumor4
  • Peripheral T-cell lymphoma (PTCL) is an aggressive tumor, rarely seen in pediatrics or adolescent and young adults (AYAs) so there is no upfront or relapsed standard of care. (bvsalud.org)
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
  • Computed tomography-based tumor volume in non-Hodgkin lymphoma: clinical correlation and comparison with magnetic resonance imaging. (medscape.com)
  • Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. (uchicago.edu)
Hematopoietic progenitor2
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • The respective mice that reconstitute human immune system components upon transplantation with CD34+ human hematopoietic progenitor cells could recapitulate aspects of EBV and HIV immunobiology observed in dual-infected patients. (hku.hk)
Mantle cell lym2
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
  • Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
Multiple myeloma3
Patients undergoing2
  • 1,000 new AML patients undergoing allogeneic or autologous HCT. (apbmt.org)
  • Seven eighty six patients undergoing allogeneic (n=550) or autologous (n=236) BMT were evaluated by physical examination, history, rest and exercise ECG, chest x-ray, two-dimensional echocardiography, and radionuclide ventriculography (RNV) before BMT, and monitored for 5 months thereafter. (slideshare.net)
Rituximab and chemotherapy1
  • A study by Salles et al determined that correlations between specific biomarkers and the international prognostic index (IPI) score demonstrate that IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy. (medscape.com)
Follicular lymphoma1
  • Follicular lymphoma (FL), a B-cell lymphoma, is the most common indolent (slow-growing) form of NHL, accounting for approximately 20 percent to 30 percent of all NHLs. (lymphomaindia.com)
DLBCL11
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for more than 30 percent of newly diagnosed cases. (lymphomaindia.com)
  • Another example is "primary mediastinal B-cell lymphoma" which often occurs in younger patients and grows rapidly in the chest (mediastinum) Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, or groin, which is caused by enlarged lymph nodes. (lymphomaindia.com)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
  • Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
  • It showed excellent efficacy and manageable safety, which actually led to the FDA approval for this drug to be used in the third-line setting for relapsed diffuse large B-cell lymphoma (DLBCL). (oncdata.com)
  • The series consisted of 10 infectious mononucleosis-like cases, 2 polymorphic, 4 monomorphic (3 Burkitt, 1 DLBCL) and 1 T cell PTLDs. (hku.hk)
Ifosfamide1
  • METHODS: Using data and specimens from the patients who had registered in the Japan Clinical Oncology Group study, JCOG0304, a phase II trial evaluating the efficacy of perioperative chemotherapy with doxorubicin (DOX) and ifosfamide (IFO), we evaluated histological response to preoperative chemotherapy at the central review board. (bvsalud.org)
Clinical9
  • Twenty-three (37%) patients remain in continuous clinical remission 1.3 to 7.7 years (median 3.8 years) after transplantation. (umn.edu)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Managed care professionals should have an understanding of the clinical trial data and place in therapy in lymphoma, myeloma, and acute lymphoblastic leukemia as well as guideline recommendations for adverse effect management associated with CAR T-cell therapies. (ajmc.com)
  • Clinical scientists continue to observe superior survival of patients treated with combined chemotherapy and radiation approaches, yet the mechanisms behind this synergistic therapeutic approach are not fully understood. (mdanderson.org)
  • Compared to the last clinical update on BALLI-01 at ASH 2021, the webcast presented data from five additional patients who received UCART22 at dose level 3 (DL3) 5x106 cells/kg after lymphodepletion with FCA. (cellectis.com)
  • In the phase 3 TRANSFORM trial, Dr. Manali Kamdar, Clinical Director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, and colleagues investigated the efficacy of lisocabtagene maraleucel (liso-cel), an anti-CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in this setting. (oncdata.com)
  • Guideline] NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. (medscape.com)
  • Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma. (ucdenver.edu)
  • DESIGN/METHODS: To determine the cumulative incidence and review the clinical data of PTLD diagnosed in the cohort of pediatric patients (<18 years) who had liver transplantation performed between 1 January 2001 and 31 December 2012 in the major liver transplantation centre (Queen Mary Hospital) of Hong Kong. (hku.hk)
Progenitor cells1
  • Independent origins of fetal liver haematopoietic stem and progenitor cells. (u-tokyo-hemat.com)
Survival3
  • The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these. (medivizor.com)
  • Rituximab has been shown to prolong survival when used therapeutically with chemotherapy in Chronic Lymphocytic Leukemia(CLL). (cancertreatmenttoday.org)
  • Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. (uchicago.edu)
Prognostic2
  • however, the prognostic significance of histological response to chemotherapy remains controversial. (bvsalud.org)
  • Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. (ucdenver.edu)
Liver transplantation2
  • RESULTS: Among 75 cases of pediatric liver transplantation performed during the study period, 17 cases of PTLD (seven males) were diagnosed, giving cumulative incidence of 6.8% at 1 year and 22% at 5 years. (hku.hk)
  • Median ages of liver transplantation and diagnosis of PTLD were 9.5 months (range: 6-51 months) and 31.2 months (range: 10-114 months), respectively. (hku.hk)
20181
  • Shanbhag, S & Ambinder, RF 2018, ' Hodgkin lymphoma: A review and update on recent progress ', CA Cancer Journal for Clinicians , vol. 68, no. 2, pp. 116-132. (johnshopkins.edu)
Combination chemotherapy1
  • Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. (uchicago.edu)
Etoposide1
Lymphoma patients2
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. (sc-ctsi.org)
Findings1
Radiation therapy3
  • Autologous BMT involves collecting and storing a patient's own healthy stem cells, which are later transplanted back into the patient's body after chemotherapy or radiation therapy. (koruhastanesi.com)
  • Peripheral blood stem cell transplantation (PBSCT) involves the collection of stem cells from the patient's blood and their subsequent infusion after chemotherapy or radiation therapy. (koruhastanesi.com)
  • Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. (ucdenver.edu)
HSCT1
  • Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). (nih.gov)
Treatment8
Relapse2
  • Some patients may not respond to chemotherapy at all while few patients respond initially but later on relapse. (lymphomaindia.com)
  • Chemotherapy was resumed without any subsequent relapse of hepatic enzyme elevation. (journaltocs.ac.uk)
Allogeneic stem2
Efficacy1
  • 2,3 Cellular therapy centers, manufacturers, payers, and policy makers will need to work together to address barriers to care as new CAR T-cell products with improved efficacy and tolerability are approved for use in more diverse malignancies. (ajmc.com)
Antigen2
  • Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)
  • CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. (bmj.com)
Positron2
  • Patients received two cycles of pembrolizumab at 200 mg on day 1 with standard salvage ICE chemotherapy every 21 days, followed by stem cell mobilization and collection, and then one cycle of pembrolizumab alone followed by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) response assessment. (ascopost.com)
  • T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging. (mdc-berlin.de)
Oncology2
  • Hematology/ Oncology and Stem Cell Therapy. (elsevierpure.com)
  • Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. (ucdenver.edu)
Aggressive2
Nodular2
  • A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. (medscape.com)
  • in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. (lookformedical.com)
Large B-cell lym4
PTCL1
  • However, results with this therapy in peripheral T-cell lymphoma (PTCL) are not well defined. (cun.es)
Conventional1
  • Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia. (u-tokyo-hemat.com)
Pediatric1
Haematopoietic1
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)